HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

human NPPA protein (carperitide)

Subscribe to New Research on human NPPA protein

RefSeq NM_006172

Also Known As:

carperitide; NPPA protein, human; alpha-atrial natriuretic peptide, human; alpha-hANP; alpha-human atrial natriuretic peptide; atrial natriuretic peptide precusor A, human; natriuretic peptide precursor A, human

Networked: 165 relevant articles (15 outcomes, 25 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sezai, Akira: 5 articles (01/2016 - 11/2006)
2.	Shiono, Motomi: 5 articles (01/2016 - 11/2006)
3.	Tsutamoto, Takayoshi: 5 articles (12/2009 - 10/2005)
4.	Wakui, Shinji: 4 articles (06/2015 - 11/2006)
5.	Horie, Minoru: 4 articles (12/2009 - 10/2005)
6.	Fujii, Masanori: 4 articles (12/2009 - 10/2005)
7.	Yamamoto, Takashi: 4 articles (12/2009 - 10/2005)
8.	Yoshitake, Isamu: 3 articles (06/2015 - 01/2013)
9.	Sugimoto, Koichi: 3 articles (01/2015 - 12/2013)
10.	Saito, Tomiyoshi: 3 articles (01/2015 - 12/2013)

Related Diseases

1.	Heart Failure 08/01/2014 - "Carperitide is effective for heart failure (HF) owing to its diuretic and vasodilatory effects. " 08/01/2014 - "This recombinant peptide may also have direct cardioprotective effects because carperitide reduces the severity of heart failure and limits infarct size. " 11/01/2008 - "Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study." 11/01/2015 - "Carperitide (α-human A-type natriuretic peptide) has been used for more than one-half of all acute heart failure (AHF) patients in Japan. " 11/01/2015 - "Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis."
2.	Ischemia 08/01/2014 - "Because coronary vasodilation is an important cardioprotective treatment modality, we investigated whether carperitide increased coronary blood flow (CBF) and improved myocardial metabolic and contractile dysfunction during ischemia in canine hearts. " 06/01/2003 - "Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts." 11/01/1987 - "The results show that a 4-h intrarenal infusion of alpha-hANP after renal ischemia can preserve glomerular filtration rate and reduce renal tissue damage." 11/01/1987 - "After ischemia, a 4-h intrarenal infusion of alpha-hANP restored 14C-inulin clearances in bilaterally and unilaterally intact animals from 0.05 +/- 0.006 and 0.05 +/- 0.01 ml/min per 100 g to 0.314 +/- 0.04 and 0.25 +/- 0.01 ml/min per 100 g, respectively (P less than 0.001, n = 8), compared with normal values of 0.49 +/- 0.023 ml/min per 100 g. " 08/01/1989 - "Thus, the infusion of alpha-hANP markedly improved the renal function of the ischemic kidney by the reconstructive surgery of the renal artery, suggesting that alpha-hANP seems clinically applicable as a protective agent in renal ischemia at renovascular surgery as well as the renal transplantation."
3.	Ventricular Remodeling 09/01/2009 - "Long-term carperitide treatment attenuates ventricular remodeling and ameliorates the progression of chronic HF. " 11/01/2006 - "Efficacy of low-dose continuous infusion of alpha-human atrial natriuretic peptide (hANP) during cardiac surgery: possibility of postoperative left ventricular remodeling effect." 09/01/2009 - "Long-term carperitide treatment attenuates left ventricular remodeling in rats with heart failure after autoimmune myocarditis."
4.	Necrosis 06/01/2010 - "I/R-induced increases in serum concentrations of BUN and creatinine and urinary concentrations of NAG were also reduced by alpha-hANP, with improved histopathological changes, including acute tubular necrosis at 24-48 h after reperfusion. " 07/01/2008 - "alpha-hANP also reduced I/R-induced increases in the concentrations of blood urea nitrogen and serum creatinine, and improved histopathologic changes, including acute tubular necrosis. "
5.	Hypertension (High Blood Pressure) 11/01/1991 - "In six patients with essential hypertension (EH) and in six healthy volunteers (C) the effects of a 60-min intravenous (iv) infusion of human atrial natriuretic peptide (alpha-hANP) (24 ng/min/kg) on systemic and renal hemodynamics and renal excretory function were evaluated. " 02/20/1990 - "After the infusion of the 0.03 micrograms/kg/min dose of alpha-hANP, systolic blood pressure fell from 115 +/- 17 mmHg to 109 +/- 15 mmHg in normal subjects, and fell significantly from 163 +/- 33 mmHg to 145 +/- 26 mmHg in patients with essential hypertension. " 12/01/1988 - "Plasma gamma-hANP(1-25)-like immunoreactivity levels were changed together with alpha-hANP-like immunoreactivity in patients with essential hypertension and adrenal disorders. " 10/01/1987 - "Renal, cardiovascular and hormonal effects of alpha-human atrial natriuretic peptide on essential hypertension." 03/01/1987 - "Patients with essential hypertension appear to have exaggerated renal responses to administered alpha-hANP, although the number of subjects studied is small and matching with normotensive controls was imperfect. "

Related Drugs and Biologics

1.	Creatinine
2.	tolvaptan
3.	Nicorandil (SG 75)
4.	Urea (Carbamide)
5.	Thyroxine (Levothyroxine)
6.	Nitrogen
7.	Epinephrine (Adrenaline)
8.	Adenosine Triphosphate (ATP)
9.	Atrial Natriuretic Factor (ANF)
10.	human NPPA protein (carperitide)

Related Therapies and Procedures

1.	Kidney Transplantation
2.	Intravenous Infusions
3.	Warm Ischemia
4.	Renal Dialysis (Hemodialysis)
5.	Ligation